The U.S. Food and Drug Administration has approved the Biologics License Application (BLA) for Novavax’s COVID-19 vaccine called Nuvaxovid™ for active immunization. 

About Nuvaxovid™

• Nuvaxovid (NVX-CoV2705) is an updated version of Novavax’s prototype COVID-19 vaccine (NVX-CoV2373) formulated to target the JN.1 variant.
• It is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID-19. 
  • The non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus
• Technology: Nuvaxovid uses Novavax’s unique recombinant nanoparticle technology with  Novavax’s Matrix-M® adjuvant enhancing and broadening the immune response. 
  • Novavax’s Matrix-M is its proprietary adjuvant that can be added to a vaccine or medicine to stimulate a stronger immune response and is currently used in globally approved vaccines.
• Feature: The vaccine is packaged as a ready-to-use liquid formulation and is stored at 2° to 8°.
• In Use: Nuvaxovid has been available for use in the U.S. under Emergency Use Authorization since July 2022.
  • It has full market approvals in the European Union, United Kingdom, Japan, Canada, Australia, Taiwan and Singapore.